RecruitingNCT06770543

Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea)

Regulatory Post-Marketing Surveillance (rPMS) Study for Leqvio® Pre-filled Syringe(Inclisiran Sodium)

Sponsor

Novartis Pharmaceuticals

Enrollment

1,500 participants

Start Date

Aug 13, 2025

Study Type

OBSERVATIONAL

Conditions

Primary Hypercholesterolemia or Mixed Dyslipidemia

Summary

This non-interventional study is a mandatory regular Post Marketing Surveillance(rPMS) granted by the Korean health authorities, and is conducted to assess the effectiveness and safety of Leqvio® Pre-filled Syringe(inclisiran sodium) in routine clinical practice for the approved indications (primary hypercholesterolemia or mixed dyslipidemia).

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Inclisiran for people with primary hypercholesterolemia or mixed dyslipidemia. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 18 Years to 100 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERInclisiran

There is no treatment allocation. Patients administered Leqvio by prescription that have started before inclusion of the patient into the study will be enrolled.

Locations(4)

Novartis Investigative Site

Yangsan, Gyeongsangnam-do, South Korea

Novartis Investigative Site

Busan, South Korea

Novartis Investigative Site

Seoul, South Korea

Novartis Investigative Site

Taegu, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06770543